增长消耗现金，要么是投资，要么是漏洞，而每期成本与合同付款的算术能在短短一页告诉你哪一种。 这个问题在医疗服务提供商中的版本并非通用版。38,000人的下行风险已接受，但缺乏定价所需每期成本数据——因此忽略每期成本的答案会自信地出错。分析必须从付款人组合和面板规模而非收入开始。
增长消耗现金，要么是投资，要么是漏洞，而每期成本与合同付款的算术能在短短一页告诉你哪一种。 这个问题在医疗服务提供商中的版本并非通用版。38,000人的下行风险已接受，但缺乏定价所需每期成本数据——因此忽略每期成本的答案会自信地出错。分析必须从付款人组合和面板规模而非收入开始。
在基于价值的合同下增加归属生命数同时亏损，如果每增加一个生命最终回报高于每期成本，就属于正常情况。如果回报低于成本，两者看起来相同，只要面板规模在增加，这就是为什么失败通常在增长停止时才被发现。
测试是按单位进行的，而且简单：当前付款人组合下服务一个额外归属生命每期成本是多少，基于价值的合同返回多少，以及周期多长。如果每个提供商的贡献为正且亏损是固定成本吸收，增长就能解决。如果每期成本超过回报，增长会加速问题，每个额外生命都会让处境更糟。
第二件要检查的事是现金时点。一个提供商集团可以在纸面上显示每个提供商的正贡献，但仍可能因付款在发生后数月才到而耗尽现金，归属生命增长越快，缺口就越大。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 归属生命数上升而现金余额下降，两者由CFO或医疗主任分别解释。
✓ 没有人能说出38,000个生命的每期成本，除非启动一个项目。
✓ 融资需求比基于价值的合同预测更早出现。
通常会让情况更糟的做法。 把亏损当作规模问题处理，而每期成本已超过合同付款，这会把可修复的面板变成更大的面板。
It is for you if you run or finance a healthcare provider and revenue rises, cash falls, and the two are explained separately. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
当亏损是固定成本吸收且单位经济为正时，是正常的。当每个额外客户都在亏损时，不是正常的，只是穿着相同衣服的不同情况。
按预期量预测当前单位经济，看线是否交叉。如果在你能合理达到的量上不交叉，增长就不是答案。
如果单位经济为负，是的，而且要立即。如果为正且约束是营运资金，问题是融资而非战略，应按此解决。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית